Type |
Details |
Score |
Gene |
Type: |
gene |
Organism: |
Not Specified |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
human |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
chimpanzee |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
cattle |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
chicken |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
macaque, rhesus |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
frog, western clawed |
|
•
•
•
•
•
|
Gene |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
dog, domestic |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
human |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
human |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
human |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
human |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
human |
|
•
•
•
•
•
|
Publication |
First Author: |
Usenko T |
Year: |
2014 |
Journal: |
PLoS One |
Title: |
Leukemogenic Ptpn11 allele causes defective erythropoiesis in mice. |
Volume: |
9 |
Issue: |
10 |
Pages: |
e109682 |
|
•
•
•
•
•
|
Publication |
First Author: |
Griger J |
Year: |
2017 |
Journal: |
Elife |
Title: |
Loss of Ptpn11 (Shp2) drives satellite cells into quiescence. |
Volume: |
6 |
|
|
|
•
•
•
•
•
|
Publication |
First Author: |
Yang Z |
Year: |
2008 |
Journal: |
Exp Hematol |
Title: |
Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival. |
Volume: |
36 |
Issue: |
10 |
Pages: |
1285-96 |
|
•
•
•
•
•
|
Publication |
First Author: |
Schramm C |
Year: |
2012 |
Journal: |
Am J Physiol Heart Circ Physiol |
Title: |
The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling. |
Volume: |
302 |
Issue: |
1 |
Pages: |
H231-43 |
|
•
•
•
•
•
|
Publication |
First Author: |
Chan G |
Year: |
2011 |
Journal: |
Blood |
Title: |
Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. |
Volume: |
117 |
Issue: |
16 |
Pages: |
4253-61 |
|
•
•
•
•
•
|
Publication |
First Author: |
Dong L |
Year: |
2016 |
Journal: |
Nature |
Title: |
Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. |
Volume: |
539 |
Issue: |
7628 |
Pages: |
304-308 |
|
•
•
•
•
•
|
Publication |
First Author: |
Yang W |
Year: |
2013 |
Journal: |
Nature |
Title: |
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. |
Volume: |
499 |
Issue: |
7459 |
Pages: |
491-5 |
|
•
•
•
•
•
|
Publication |
First Author: |
Chan G |
Year: |
2009 |
Journal: |
Blood |
Title: |
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. |
Volume: |
113 |
Issue: |
18 |
Pages: |
4414-24 |
|
•
•
•
•
•
|
Publication |
First Author: |
Liu X |
Year: |
2016 |
Journal: |
Proc Natl Acad Sci U S A |
Title: |
Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies. |
Volume: |
113 |
Issue: |
4 |
Pages: |
984-9 |
|
•
•
•
•
•
|
Publication |
First Author: |
Marin TM |
Year: |
2011 |
Journal: |
J Clin Invest |
Title: |
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. |
Volume: |
121 |
Issue: |
3 |
Pages: |
1026-43 |
|
•
•
•
•
•
|
Publication |
First Author: |
Ventura PMO |
Year: |
2022 |
Journal: |
EMBO Rep |
Title: |
Concomitant deletion of Ptpn6 and Ptpn11 in T cells fails to improve anticancer responses. |
Volume: |
23 |
Issue: |
11 |
Pages: |
e55399 |
|
•
•
•
•
•
|
Publication |
First Author: |
Araki T |
Year: |
2009 |
Journal: |
Proc Natl Acad Sci U S A |
Title: |
Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. |
Volume: |
106 |
Issue: |
12 |
Pages: |
4736-41 |
|
•
•
•
•
•
|
Publication |
First Author: |
Liu W |
Year: |
2017 |
Journal: |
Leukemia |
Title: |
Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations. |
Volume: |
31 |
Issue: |
6 |
Pages: |
1415-1422 |
|
•
•
•
•
•
|
Publication |
First Author: |
Xu D |
Year: |
2013 |
Journal: |
PLoS One |
Title: |
Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder. |
Volume: |
8 |
Issue: |
5 |
Pages: |
e63152 |
|
•
•
•
•
•
|
Publication |
First Author: |
Araki T |
Year: |
2004 |
Journal: |
Nat Med |
Title: |
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. |
Volume: |
10 |
Issue: |
8 |
Pages: |
849-57 |
|
•
•
•
•
•
|
Publication |
First Author: |
Zhang W |
Year: |
2009 |
Journal: |
J Biol Chem |
Title: |
Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia. |
Volume: |
284 |
Issue: |
33 |
Pages: |
22353-63 |
|
•
•
•
•
•
|
Publication |
First Author: |
Chen L |
Year: |
2015 |
Journal: |
Leukemia |
Title: |
Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. |
Volume: |
29 |
Issue: |
6 |
Pages: |
1290-300 |
|
•
•
•
•
•
|
Publication |
First Author: |
Xu D |
Year: |
2010 |
Journal: |
Blood |
Title: |
A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. |
Volume: |
116 |
Issue: |
18 |
Pages: |
3611-21 |
|
•
•
•
•
•
|
Publication |
First Author: |
Xu D |
Year: |
2011 |
Journal: |
J Exp Med |
Title: |
Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells. |
Volume: |
208 |
Issue: |
10 |
Pages: |
1977-88 |
|
•
•
•
•
•
|
Publication |
First Author: |
Yang Z |
Year: |
2009 |
Journal: |
Mol Cell Biol |
Title: |
Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants. |
Volume: |
29 |
Issue: |
16 |
Pages: |
4376-93 |
|
•
•
•
•
•
|
Publication |
First Author: |
Zheng H |
Year: |
2013 |
Journal: |
J Biol Chem |
Title: |
Induction of a tumor-associated activating mutation in protein tyrosine phosphatase Ptpn11 (Shp2) enhances mitochondrial metabolism, leading to oxidative stress and senescence. |
Volume: |
288 |
Issue: |
36 |
Pages: |
25727-38 |
|
•
•
•
•
•
|
Publication |
First Author: |
Tarnawsky SP |
Year: |
2017 |
Journal: |
Dev Dyn |
Title: |
Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice. |
Volume: |
246 |
Issue: |
12 |
Pages: |
1001-1014 |
|
•
•
•
•
•
|
Publication |
First Author: |
Kontaridis MI |
Year: |
2008 |
Journal: |
Circulation |
Title: |
Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways. |
Volume: |
117 |
Issue: |
11 |
Pages: |
1423-35 |
|
•
•
•
•
•
|
Publication |
First Author: |
Hill KS |
Year: |
2019 |
Journal: |
Mol Cancer Res |
Title: |
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas. |
Volume: |
17 |
Issue: |
2 |
Pages: |
583-593 |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
276
|
Fragment?: |
true |
|
•
•
•
•
•
|
Publication |
First Author: |
Paardekooper Overman J |
Year: |
2014 |
Journal: |
Mol Cell Biol |
Title: |
PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice. |
Volume: |
34 |
Issue: |
15 |
Pages: |
2874-89 |
|
•
•
•
•
•
|
Publication |
First Author: |
Edwards MA |
Year: |
2015 |
Journal: |
J Appl Physiol (1985) |
Title: |
The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration. |
Volume: |
118 |
Issue: |
1 |
Pages: |
124-31 |
|
•
•
•
•
•
|
Publication |
First Author: |
Zhao H |
Year: |
2019 |
Journal: |
Oncogene |
Title: |
Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis. |
Volume: |
38 |
Issue: |
13 |
Pages: |
2275-2290 |
|
•
•
•
•
•
|
Publication |
First Author: |
Gu S |
Year: |
2018 |
Journal: |
Leukemia |
Title: |
SHP2 is required for BCR-ABL1-induced hematologic neoplasia. |
Volume: |
32 |
Issue: |
1 |
Pages: |
203-213 |
|
•
•
•
•
•
|
Publication |
First Author: |
Coulombe G |
Year: |
2013 |
Journal: |
Mol Cell Biol |
Title: |
Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice. |
Volume: |
33 |
Issue: |
11 |
Pages: |
2275-84 |
|
•
•
•
•
•
|
Publication |
First Author: |
Li XJ |
Year: |
2015 |
Journal: |
J Biol Chem |
Title: |
Protein-tyrosine phosphatase Shp2 positively regulates macrophage oxidative burst. |
Volume: |
290 |
Issue: |
7 |
Pages: |
3894-909 |
|
•
•
•
•
•
|
Publication |
First Author: |
Lapinski PE |
Year: |
2013 |
Journal: |
Dis Model Mech |
Title: |
Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity, and calvarial defects in mice. |
Volume: |
6 |
Issue: |
6 |
Pages: |
1448-58 |
|
•
•
•
•
•
|
Publication |
First Author: |
Yi JS |
Year: |
2016 |
Journal: |
JCI Insight |
Title: |
Low-dose dasatinib rescues cardiac function in Noonan syndrome. |
Volume: |
1 |
Issue: |
20 |
Pages: |
e90220 |
|
•
•
•
•
•
|
Publication |
First Author: |
Bellio M |
Year: |
2019 |
Journal: |
Blood |
Title: |
Catalytic dysregulation of SHP2 leading to Noonan syndromes affects platelet signaling and functions. |
Volume: |
134 |
Issue: |
25 |
Pages: |
2304-2317 |
|
•
•
•
•
•
|
Publication |
First Author: |
Tarnawsky SP |
Year: |
2018 |
Journal: |
Oncotarget |
Title: |
Hematopoietic-restricted Ptpn11E76K reveals indolent MPN progression in mice. |
Volume: |
9 |
Issue: |
31 |
Pages: |
21831-21843 |
|
•
•
•
•
•
|
Publication |
First Author: |
Liu X |
Year: |
2012 |
Journal: |
Cancer Res |
Title: |
Protein tyrosine phosphatase Shp2 (Ptpn11) plays an important role in maintenance of chromosome stability. |
Volume: |
72 |
Issue: |
20 |
Pages: |
5296-306 |
|
•
•
•
•
•
|
Publication |
First Author: |
Gagné-Sansfaçon J |
Year: |
2016 |
Journal: |
Oncotarget |
Title: |
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development. |
Volume: |
7 |
Issue: |
40 |
Pages: |
65676-65695 |
|
•
•
•
•
•
|
Publication |
First Author: |
Yi JS |
Year: |
2020 |
Journal: |
JCI Insight |
Title: |
Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines. |
Volume: |
5 |
Issue: |
15 |
|
|
•
•
•
•
•
|
Publication |
First Author: |
Nakamura T |
Year: |
2009 |
Journal: |
Proc Natl Acad Sci U S A |
Title: |
Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development. |
Volume: |
106 |
Issue: |
27 |
Pages: |
11270-5 |
|
•
•
•
•
•
|
Publication |
First Author: |
Bowen ME |
Year: |
2014 |
Journal: |
PLoS Genet |
Title: |
SHP2 regulates chondrocyte terminal differentiation, growth plate architecture and skeletal cell fates. |
Volume: |
10 |
Issue: |
5 |
Pages: |
e1004364 |
|
•
•
•
•
•
|
Publication |
First Author: |
Yi JS |
Year: |
2021 |
Journal: |
Cardiovasc Drugs Ther |
Title: |
Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines. |
|
|
|
|
•
•
•
•
•
|
Publication |
First Author: |
Wang J |
Year: |
2017 |
Journal: |
PLoS One |
Title: |
In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy. |
Volume: |
12 |
Issue: |
6 |
Pages: |
e0178905 |
|
•
•
•
•
•
|
Publication |
First Author: |
Tajan M |
Year: |
2014 |
Journal: |
Proc Natl Acad Sci U S A |
Title: |
LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity. |
Volume: |
111 |
Issue: |
42 |
Pages: |
E4494-503 |
|
•
•
•
•
•
|
Publication |
First Author: |
Zheng H |
Year: |
2018 |
Journal: |
Sci Signal |
Title: |
Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner. |
Volume: |
11 |
Issue: |
522 |
|
|
•
•
•
•
•
|
Publication |
First Author: |
Zuo C |
Year: |
2018 |
Journal: |
Bone Res |
Title: |
SHP2 regulates skeletal cell fate by modifying SOX9 expression and transcriptional activity. |
Volume: |
6 |
|
Pages: |
12 |
|
•
•
•
•
•
|
Publication |
First Author: |
Saxton TM |
Year: |
2000 |
Journal: |
Nat Genet |
Title: |
The SH2 tyrosine phosphatase shp2 is required for mammalian limb development. |
Volume: |
24 |
Issue: |
4 |
Pages: |
420-3 |
|
•
•
•
•
•
|
Publication |
First Author: |
Deng L |
Year: |
2018 |
Journal: |
Oncotarget |
Title: |
Rapid development of myeloproliferative neoplasm in mice with Ptpn11D61Y mutation and haploinsufficient for Dnmt3a. |
Volume: |
9 |
Issue: |
5 |
Pages: |
6055-6061 |
|
•
•
•
•
•
|
Publication |
First Author: |
Altmüller F |
Year: |
2017 |
Journal: |
PLoS Genet |
Title: |
Aberrant neuronal activity-induced signaling and gene expression in a mouse model of RASopathy. |
Volume: |
13 |
Issue: |
3 |
Pages: |
e1006684 |
|
•
•
•
•
•
|
Publication |
First Author: |
Wang L |
Year: |
2021 |
Journal: |
FASEB J |
Title: |
SHP2 regulates the development of intestinal epithelium by modifying OSTERIX+ crypt stem cell self-renewal and proliferation. |
Volume: |
35 |
Issue: |
1 |
Pages: |
e21106 |
|
•
•
•
•
•
|
Publication |
First Author: |
Weiss EM |
Year: |
2024 |
Journal: |
Front Cell Neurosci |
Title: |
Developmental effect of RASopathy mutations on neuronal network activity on a chip. |
Volume: |
18 |
|
Pages: |
1388409 |
|
•
•
•
•
•
|
Publication |
First Author: |
Wang L |
Year: |
2018 |
Journal: |
FASEB J |
Title: |
A ERK/RSK-mediated negative feedback loop regulates M-CSF-evoked PI3K/AKT activation in macrophages. |
Volume: |
32 |
Issue: |
2 |
Pages: |
875-887 |
|
•
•
•
•
•
|
Publication |
First Author: |
Chen B |
Year: |
2000 |
Journal: |
Nat Genet |
Title: |
Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. |
Volume: |
24 |
Issue: |
3 |
Pages: |
296-9 |
|
•
•
•
•
•
|
Publication |
First Author: |
De Rocca Serra-Nédélec A |
Year: |
2012 |
Journal: |
Proc Natl Acad Sci U S A |
Title: |
Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature. |
Volume: |
109 |
Issue: |
11 |
Pages: |
4257-62 |
|
•
•
•
•
•
|
Publication |
First Author: |
Ehrman LA |
Year: |
2014 |
Journal: |
J Neurosci |
Title: |
The protein tyrosine phosphatase Shp2 is required for the generation of oligodendrocyte progenitor cells and myelination in the mouse telencephalon. |
Volume: |
34 |
Issue: |
10 |
Pages: |
3767-78 |
|
•
•
•
•
•
|
Publication |
First Author: |
Ruess DA |
Year: |
2018 |
Journal: |
Nat Med |
Title: |
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. |
Volume: |
24 |
Issue: |
7 |
Pages: |
954-960 |
|
•
•
•
•
•
|
Publication |
First Author: |
Tebbutt NC |
Year: |
2002 |
Journal: |
Nat Med |
Title: |
Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. |
Volume: |
8 |
Issue: |
10 |
Pages: |
1089-97 |
|
•
•
•
•
•
|
Publication |
First Author: |
Gong H |
Year: |
2019 |
Journal: |
J Mol Cell Cardiol |
Title: |
Shp2 in myocytes is essential for cardiovascular and neointima development. |
Volume: |
137 |
|
Pages: |
71-81 |
|
•
•
•
•
•
|
Publication |
First Author: |
Li K |
Year: |
2014 |
Journal: |
J Neurosci |
Title: |
Shp2-dependent ERK signaling is essential for induction of Bergmann glia and foliation of the cerebellum. |
Volume: |
34 |
Issue: |
3 |
Pages: |
922-31 |
|
•
•
•
•
•
|
Publication |
First Author: |
Krenz M |
Year: |
2008 |
Journal: |
Proc Natl Acad Sci U S A |
Title: |
Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome. |
Volume: |
105 |
Issue: |
48 |
Pages: |
18930-5 |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
Mus caroli |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
Mus pahari |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
Mus spretus |
|
•
•
•
•
•
|
Publication |
First Author: |
Ai J |
Year: |
2006 |
Journal: |
Blood |
Title: |
The inositol phosphatase SHIP-2 down-regulates FcgammaR-mediated phagocytosis in murine macrophages independently of SHIP-1. |
Volume: |
107 |
Issue: |
2 |
Pages: |
813-20 |
|
•
•
•
•
•
|
Publication |
First Author: |
Salmond RJ |
Year: |
2005 |
Journal: |
J Immunol |
Title: |
The src homology 2 domain-containing tyrosine phosphatase 2 regulates primary T-dependent immune responses and Th cell differentiation. |
Volume: |
175 |
Issue: |
10 |
Pages: |
6498-508 |
|
•
•
•
•
•
|
Publication |
First Author: |
Zhu Y |
Year: |
2018 |
Journal: |
Mol Med Rep |
Title: |
Loss of Shp2 within radial glia is associated with cerebral cortical dysplasia, glial defects of cerebellum and impaired sensory‑motor development in newborn mice. |
Volume: |
17 |
Issue: |
2 |
Pages: |
3170-3177 |
|
•
•
•
•
•
|
Publication |
First Author: |
Fornaro M |
Year: |
2006 |
Journal: |
J Cell Biol |
Title: |
SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth. |
Volume: |
175 |
Issue: |
1 |
Pages: |
87-97 |
|
•
•
•
•
•
|
Publication |
First Author: |
Verma R |
Year: |
2015 |
Journal: |
Mol Cell Biol |
Title: |
Shp2 Associates with and Enhances Nephrin Tyrosine Phosphorylation and Is Necessary for Foot Process Spreading in Mouse Models of Podocyte Injury. |
Volume: |
36 |
Issue: |
4 |
Pages: |
596-614 |
|
•
•
•
•
•
|
Publication |
First Author: |
Lee YS |
Year: |
2014 |
Journal: |
Nat Neurosci |
Title: |
Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome. |
Volume: |
17 |
Issue: |
12 |
Pages: |
1736-43 |
|
•
•
•
•
•
|
Publication |
First Author: |
Hsu MF |
Year: |
2017 |
Journal: |
Sci Rep |
Title: |
Protein tyrosine phosphatase Shp2 deficiency in podocytes attenuates lipopolysaccharide-induced proteinuria. |
Volume: |
7 |
Issue: |
1 |
Pages: |
461 |
|
•
•
•
•
•
|